表紙
市場調查報告書

CAR-T細胞療法市場檢討

CAR-T Cell Therapy Market Review

出版商 Kalorama Information 商品編碼 922775
出版日期 內容資訊 英文 59 Pages
商品交期: 最快1-2個工作天內
價格
CAR-T細胞療法市場檢討 CAR-T Cell Therapy Market Review
出版日期: 2019年12月19日內容資訊: 英文 59 Pages
簡介

CAR-T細胞療法,是利用身體的T細胞以癌症細胞為標的並破壞的免疫療法之一。這個治療方法是配合個人的治療方法,各患者接受專門用於癌症診斷的T細胞。T細胞療法,除去患者現有的T細胞,在實驗室中對其進行成長及改變以作用。這些新的T細胞,給予稱為嵌合抗原受體(CAR)的特殊受體的遺傳基因,允許細胞特異性攻擊癌細胞。 CAR-T細胞療法,尤其是對急性淋巴芽球性白血病(ALL),DLBCL B細胞淋巴瘤,多發性骨髓瘤的疾病,顯示消除癌症細胞的有效性。

本報告提供CAR-T細胞療法市場相關調查,市場趨勢,課題,及近幾年的發展趨勢等相關分析。

第1章 摘要整理

第2章 CAR-T細胞療法市場

  • FDA核准完畢的CAR-T療法:YESCARTA及KYMRIAH
  • CAR-T細胞療法市場趨勢/課題
  • 最近的市場開發
  • 開發中的主要CAR-T療法
  • CAR-T市場分析

第3章 市場參與企業

  • ABBVIE,INC.
  • AUTOLUS THERAPEUTICS PLC
  • BELLICUM PHARMACEUTICALS, INC.
  • BLUEBIRD BIO, INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • CARSGEN THERAPEUTICS
  • CELGENE CORPORATION
  • CELLECTIS, INC.
  • CELYAD
  • GILEAD SCIENCES,INC.
  • GLAXOSMITHKLINE
  • GRACELL BIOTECHNOLOGY
  • IMMUNE THERAPEUTICS
  • INNOVATIVE CELLULAR THERAPEUTICS
  • JUNO THERAPEUTICS
  • KITE PHARMA, INC.
  • MUSTANG BIO
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC.
  • SORRENTO THERAPEUTICS
  • ZIOPHARM ONCOLOGY,INC
目錄
Product Code: 19-099

CAR-T cell therapy is a form of immunotherapy that utilizes the body's own T cells to target and destroy cancer cells. This therapy is a personalized form of treatment, meaning that each patient receives T cells that are geared specifically toward his or her cancer diagnosis. T-cell therapy works by removing existing T cells from a patient and having them grown and modified in a lab. These new T cells are given a gene for a specialized receptor, known as a chimeric antigen receptor (CAR), which allows the cells to specifically attack cancer cells. CAR-T cell therapy has shown effectiveness in eliminating cancer cells, especially for the following diseases:

  • Acute lymphoblastic leukemia (ALL)
  • DLBCL B-cell lymphomas
  • Multiple myeloma

‘CAR-T Cell Therapy Market Review’ discusses CAR-T's impressive revenue growth, which is expected to continue given the effectiveness of the therapy and the projected new users. There are positive factors for the market, though there are limits to growth. Patient volume should increase, though it is likely that the unusually large prices will not sustain over the next five years. The report provides the following market data:

  • CAR-T Market, 2018-2024 ($millions)
  • CAR-T Market Share, 2019 (%)
  • CAR-T Market Regional Breakout, 2019 (%)

‘CAR-T Cell Therapy Market Review’ discusses CAR-T therapy market trends, issues, and recent developments, including the following:

  • Global Cancer Burden
  • Complexity of the CARs Manufacturing Process
  • Diseases Treated with CAR-T
  • Study Shows Yescarta Increases Longevity
  • CRS and Other Side Effects
  • China CAR-T Competition
  • Indian CAR-T Competition
  • "Off-the-Shelf" CAR-T Therapies in Development
  • Competing Therapy in Development

Also noted in the report are selected CAR-T therapies in development, an effort to capture current media coverage of CAR-T trials.

‘CAR-T Cell Therapy Market Review’ notes the activities of many of the major players in the market. The market companies that are covered in the report are the following:

  • AbbVie, Inc.
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellectis, Inc.
  • Celyad
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Immune Therapeutics
  • Innovative Cellular Therapeutics
  • Juno Therapeutics
  • Kite Pharma, Inc.
  • Mustang Bio
  • Novartis International AG
  • Pfizer, Inc.
  • Sorrento Therapeutics
  • ZIOPHARM Oncology, Inc.

Table of Contents

1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • CAR-T THERAPY MARKET TRENDS, ISSUES, AND RECENT DEVELOPMENTS
  • CAR-T THERAPY MARKET
  • COMPANIES IN THE MARKET

2: CAR-T CELL THERAPY MARKET

  • FDA-APPROVED CAR-T THERAPIES: YESCARTA AND KYMRIAH
    • Yescarta
    • Kymriah
      • Table 2-1: FDA-Approved CAR-T Therapies
  • CAR-T THERAPY MARKET TRENDS / ISSUES
    • Global Cancer Burden
      • Figure 2-1: Global Cancer Incidence Trends, 2010-2040
    • Complexity of the CARs Manufacturing Process
    • Diseases Treated with CAR-T
  • RECENT MARKET DEVELOPMENTS
    • Study Shows Yescarta Increases Longevity
    • CRS and Other Side Effects
    • China CAR-T Competition
    • Indian CAR-T Competition
    • "Off-the-Shelf" CAR-T Therapies in Development
  • A Competing Therapy in Development
  • SELECTED CAR-T THERAPIES IN DEVELOPMENT
    • Table 2-2: Selected CAR-T Therapies in Development
  • KTE-X19
  • liso-cel
  • C-CAR088
  • IBI326 (Innovent) / CT103A (IASO BIO)
  • bb21217
  • MB-107
  • ICTCAR014
  • bb2121
  • JNJ-682284528 (JNJ-4528)
  • CT053
  • MB-101 (IL-13Rα2)
  • MB-108 (oncolytic virus C134)
  • CYAD-01
  • BAFF-R CAR-T
  • MB-105 (PSCA)
  • MB-102 (CD123)
  • MB-103 (HER2)
  • P-BCMA-101
  • LCAR-B38M
  • JCARH125
  • MCARH171
  • CYAD-101
  • MB-106 (CD20)
  • MB-104 (CS1)
  • AMG 119
  • ATA2271
  • AUTO1
  • AUTO3
  • CAR-T MARKET ANALYSIS
    • Figure 2-2: CAR-T Market, 2018-2024 ($millions)
    • Market Share
      • Figure 2-3: CAR-T Market Share, 2019 (%)
    • Regional Breakout
      • Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)

3: COMPANIES IN THE MARKET

  • ABBVIE, INC.
    • Company Summary
    • Scripps Research Institute Deal
    • Tyrosine Kinase Inhibitors Market
  • AUTOLUS THERAPEUTICS PLC
  • BELLICUM PHARMACEUTICALS, INC.
  • BLUEBIRD BIO, INC.
    • Company Summary
    • bb2121
    • bb21217
    • bb2121
  • BRISTOL-MYERS SQUIBB COMPANY
    • Company Summary
    • BMS Acquires Celgene
    • Monoclonal Antibodies Market
    • Cancer Kinase Inhibitor Market
  • CARSGEN THERAPEUTICS
  • CELGENE CORPORATION
    • Company Summary
    • Collaboration with Immatics Biotechnologies
    • Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
    • Celgene Buys JAK2 Inhibitor Maker
  • CELLECTIS, INC.
    • Pfizer
    • Servier
  • CELYAD
    • CYAD-01
    • CYAD-101
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE
  • GRACELL BIOTECHNOLOGY
  • IMMUNE THERAPEUTICS
    • CAR-T
  • INNOVATIVE CELLULAR THERAPEUTICS
    • ICTCAR014
  • JUNO THERAPEUTICS
    • Selected CAR-T Therapies in Development
    • Collaboration with Editas Medicine
  • KITE PHARMA, INC.
    • KTE-X19
    • Yescarta
  • MUSTANG BIO
  • NOVARTIS INTERNATIONAL AG
    • Company Summary
    • Kymriah
    • Intellia Therapeutics
    • Other Company Activity
  • PFIZER, INC.
  • SORRENTO THERAPEUTICS
  • ZIOPHARM ONCOLOGY, INC